# FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis

Source: https://onco.cc/trials/nct06801665/  
OnCo record `nct06801665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Hua Jiang, now recruiting.

## Summary

FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis is a phase 2, interventional study registered as NCT06801665 by Hua Jiang, with a registry enrolment figure of 30 participants, started 2025-04-17 and due to reach its primary completion in 2027-02-01. Interventions recorded: FMT+QL1706+Bevacizumab+XELOX. Conditions listed: Colorectal Cancer Liver Metastasis. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "Histological or cytological confirmed advanced colorectal cancer with liver metastasis". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06801665
- Phase: 2
- Setting: Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study
- Sponsor: Hua Jiang
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06801665: https://clinicaltrials.gov/study/NCT06801665

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06801665.json